Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort

BACKGROUND: Trastuzumab was introduced a decade ago and has improved outcomes for HER2-positive breast cancer. We investigated the factors predictive of pathological complete response (pCR), prognostic factors for disease-free survival (DFS), and interactions between pCR and DFS after neoadjuvant tr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Cancer
Auteurs principaux: Hamy-Petit, Anne-Sophie, Belin, Lisa, Bonsang-Kitzis, Hélène, Paquet, Caroline, Pierga, Jean-Yves, Lerebours, Florence, Cottu, Paul, Rouzier, Roman, Savignoni, Alexia, Lae, Marick, Reyal, Fabien
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Translational Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4716543/
https://ncbi.nlm.nih.gov/pubmed/26657653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.426
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires